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Plasma ghrelin level in children with type 1 diabetes mellitus  
 
INTRODUCTION 
Type-1 diabetes mellitus (T1DM) is the commonest 
endocrine-metabolic disease in childhood1. 
Incidence of T1DM in Egypt in children less than 
15 years ranged from 5% to 9.99%2,3. Ghrelin is a 
28-amino-acid peptide hormone that is secreted  
 
 
predominantly by P/D1 cells lining the fundus of 
the human stomach and epsilon cells of the 
pancreas that stimulates appetite4, with lesser 
amounts secreted by other cells as in the 
hypothalamic arcuate nucleus, where it stimulates 
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the secretion of growth hormone from the anterior 
pituitary gland5.   
Aim of the study: Measurement of pre-prandial 
plasma ghrelin level in children with T1DM and to 
clarify the relationship between its level  and some 
parameters that may affect it as body mass index 
(BMI), serum glucose and glycosylated hemoglobin 




This study included 88 children. Sixty-six children 
with T1DM using conventional criteria as classic 
clinical picture (of polyuria, polydipsia and weight 
loss) and blood sugar>200mg/dl and positive islet 
cell antibodies(ICA) and positive glutamic acid 
decarboxylase (GAD) antibodies and 22 apparently 
healthy children serving as controls. Diabetic 
children were selected from the Diabetes Clinic and 
Inpatient Pediatric Department, Minia University 
Hospital during the period from April 2009 to 
March 2010. 
The study population was grouped into:  
Group A: included 22 children with new onset 
diabetes mellitus that diagnosed according to 
criteria adapted by the American Diabetes 
Association 20076. They were 11 males and 11 
females, aged from 7 to 10 years with a mean 9.04 
± 1.04 years.  
Group B: included 22 children with good glycemic 
controlled diabetes mellitus (HbA1c less than 8%)6 
on insulin therapy. They were 11 males and 11 
females, aged from 7 to 10 years with a mean of 9.2 
± 1.0 years.  
Group C: included 22 children with poor glycemic 
controlled diabetic patients (HbA1c more than 8%)6 
on insulin therapy. They were 13 males and 9 
females, aged from 6 to 10 years with a mean of 8.7 
± 1.6 years. 
Group D: included 22 apparently normal healthy 
children with age and sex matched serving as 
control group. They were 12 males and 10 females, 
aged from 7 to 10 years with a mean of 9.1 ± 1.1 
years. This prospective study was approved by 
Minia University Council and Faculty of Medicine 
Council and written consents were taken from 
children fathers or care takers before study . 
Exclusion criteria: Comatose  children,  
children with diabetic ketoacidosis, children with 
type-II diabetes mellitus and children with transient 
hyperglycemia with acute concurrent illness.  
All children after careful history taking, 
thorough complete clinical examination underwent 
the following laboratory investigations: Five mls of 
venous blood withdrawn under complete aseptic 
conditions, two ml of them collected onto 500µ 
aprotinin and EDTA (1.2 mg/ml blood) and 
centrifuged. The obtained plasma was separated 
then stored at -50˚C till the time of assay of the 
quantification plasma levels of active ghrelin. Pre-
prandial plasma ghrelin level was assayed using 
enzyme linked immunosorbant assay (ELISA)7 
which is based on a double-antibody sandwich 
technique8. Another three ml of blood were used for 
HbA1C measurement using resin column 
chromatography9, fasting and two-hour post-
prandial blood glucose levels, liver function tests, 
renal function tests and serum cholesterol and 
triglyceride using konelab (an automated clinical 
chemistry). 
 
Statistical analysis:  
Values are given as means ± SD, range, or as the 
number of subjects and proportions. The student t 
test was used for group comparisons of normally 
distributed variables, and the Mann-Whitney U test 
and Wilcoxon signed-rank test were used for 
comparisons of variables with skewed distribution. 
The chi square test was used to compare 
proportions. Correlation coefficients were used to 
describe associations between variables, and 
multiple regression analysis was used to detect any 
relationships between the variables. P < 0.05 was 
considered significant. Analyses were performed 




Multiple regression analysis of factors affecting the 
ghrelin concentration among the studied groups 
revealed that the most important factors affecting 
ghrelin concentration were FBG followed by 2h 
post-prandial glucose, weight, BMI,……., while the 
least important factor was the sex.   
Comparison between the levels of urea, 
creatinine, ALT, AST and serum albumin between 
each diabetic group and controls revealed 
insignificant differences, also comparison between 
the levels ghrelin levels between males and females 
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Table 2. Comparison between cases subgroups as regards demographic, clinical and laboratory data. 
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Table 3. Comparison between cases subgroups as regards demographic, clinical and laboratory data. 
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0.001** 0.3 0.001** 
*=significant                                    **= highly significant. 
P1 Comparison between new onset DM-1 and control groups. 
P2 Comparison between good glycemic control and control groups. 







Table 4. Comparison between cases subgroups as regards demographic, clinical and laboratory data. 
Variables 
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0.001** 0.5 0.001** 
*=significant                                    **= highly significant. 
P1 Comparison between new onset DM-1 and control groups. 
P2 Comparison between good glycemic control and control groups. 
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Table 5. Correlation between ghrelin concentration and some demographic,  










Age (years) 0.12 (0.5) 0.05 (0.8) 0.09(0.6) 
Weight (Kg) -0.51(0.009**) -0.44 (0.03*) -0.57(0.003**) 
Weight on centile -0.47 (0.02*) -0.46 (0.03*) -0.53(0.008**) 
Height (Cm) -0.03 (0.8) 0.23 (0.2) -0.23(0.2) 
Height on centile 0.17 (0.4) 0.23 (0.2) 0.12 (0.6) 
BMI -0.47 (0.02*) -0.45 (0.03*) -0.58(0.004**) 
BMI on centile -0.48 (0.02*) -0.41 (0.04*) -0.47(0.02*) 
FBG (mg/dl) -0.70 (0.001**) -0.46 (0.02*) -0.60(0.004**) 
2 hour post prandial glucose (mg/dl) -0.46 (0.02*) -0.46 (0.03*) -0.57 (0.005**) 
HbA1c  % 0.24 (0.2) 0.20 (0.3) 0.30 (0.4) 
Total cholesterol (mg/dl) -0.11 (0.6) -0.09 (0.6) 0.02(0.9) 
Triglycerides (mg/dl) -0.22(0.3) 0.24 (0.1) 0.12 (0.5) 
Urea (mg/dl) 0.24 (0.2) -0.13 (0.5) 0.06(0.7) 
Creatinine (mg/dl) 0.23 (0.2) -0.09 (0.6) 0.09(0.6) 
ALT (u/l) 0.17(0.4) 0.24(0.2) 0.15(0.4) 
AST (u/l) 0.21(0.3) 0.02(0.9) -0.05(0.8) 
Serum albumin (g/dl) -0.19(0.3) -0.24(0.1) -0.24(0.1) 
 
DISCUSSION 
Ghrelin, a hormone that is produced mainly by the 
stomach, was identified originally as the 
endogenous ligand of the growth hormone 
secretagogue (GHS) receptor10,11. Ghrelin might 
also be synthesized in other organs, where it might 
have autocrine and/or paracrine effects. GHS 
receptors are present in tissues other than the 
hypothalamus and pituitary, which indicates that 
ghrelin has other effects in addition to stimulating 
the release of growth hormone12. 
Rindi et al., 200213 reported that there is a new 
cell type in the human pancreas that produces 
ghrelin. The pancreas also expresses GHS-R14; 
hence, in addition to stimulating GH secretion15, 
controlling food intake, fat utilization, and fat 
synthesis16-18, ghrelin may play an important role in 
glucose and insulin metabolism. 
In the present study, both of weight, weight on 
centile, BMI and BMI on centile were significantly 
lower in newly diagnosed and poorly controlled 
diabetic children than controls. On the contrary, we 
found an increase in the weight and BMI of the 
good glycemic group to be almost near that of 
controls. In spite of orixigenic effect of ghrelin 
which increases food intake and leads to increase of 
BMI, this is not apparent in newly diagnosed and 
poorly controlled diabetic children which may be 
referred to the catabolic effect of insulin deficiency 
and the important role of insulin itself for ghrelin 
actions. 
These results were is in agreement with Martos-
Moreno et al,200619 who demonstrated that diabetic 
children with T1DM had decreased BMI at the time 
of diagnosis and normalized after 1 month of 
insulin therapy. Also this is in agreement with other 
studies20,21 who  reported a significant increase in 
weight and BMI in diabetic patients after insulin 
therapy. This was associated with a significant 
decrease in glucose levels and HbA1c. 
As anticipated, our results showed that fasting 
blood glucose, 2 hours post-prandial glucose, 
HbA1c, serum cholesterol and triglycerides levels 
were significantly higher in newly-diagnosed and 
poorly glycemic diabetic children when compared 
with controls, but there was no statistically 
significant difference between good glycemic 
controlled diabetic children and controls. 
The combination of insulin deficiency and 
elevated levels of the counter-regulatory hormones 
are responsible for promoting glycogenolysis, 
gluconeogenesis, while decreasing glucose 
utilization, glucose clearance, also accelerated 
lipolysis and impaired lipid synthesis, with resulting 
increased plasma concentrations of total lipids, 
cholesterol, triglycerides, and free fatty acids22. 
In the present study, the results showed a 
significant higher level of ghrelin in children with 
newly-diagnosed diabetes mellitus than controls. 
This is in agreement with other authors who 
reported that in diabetic patients, the mean plasma 
ghrelin level was significantly higher at the time of 
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diagnosis with significant reduction of its level after 
3 month of insulin therapy21. 
Soriano-Guillen et al., 200420 on the contrary 
found that in diabetic patients, the mean plasma 
ghrelin levels were significantly lower than controls 
at the time of diagnosis. They hypothesized that the 
high glucose levels found at the onset of diabetes 
inhibit ghrelin secretion. As ghrelin has been shown 
to stimulate hyperglycemia24,25, hence in situations 
of elevated glucose concentrations the organism 
may respond by decreasing ghrelin levels so that it 
does not contribute to a further increase in glucose 
concentrations, so it may be a defensive mechanism 
against hyperglycemia.  
The difference between Soriano-Guillen et al., 
200420 and our results may be attributed to higher 
BMI of diabetic children in their study in 
comparison to our patients, and since the inverse 
association between plasma ghrelin and both of 
weight and BMI in children is well established23 
this may contribute to decreased plasma ghrelin 
level in their study. 
The hyperglycemic effect of ghrelin might 
result from the endocrine effects of ghrelin as well 
as from its direct effects on hepatocytes in which it 
modulates glycogen synthesis and gluconeogenesis,  
ghrelin stimulates hepatic glucose production24, 
inhibits insulin secretion both in vitro and in most 
human and animal studies25 and stimulates secretion 
of the counter-regulatory hormones, including GH, 
cortisol, adrenaline26 and possibly glucagon27. Thus 
increased plasma ghrelin may lead to 
hyperglycemia by the previous mechanisms. But it 
is not clear whether the inappropriate ghrelin 
responses independently contribute to 
hyperglycemia of the disease or are merely a 
consequence of insufficient insulin secretion from 
the islet28. 
In the present study, there was a significantly 
higher plasma level of ghrelin in poor glycemic 
controlled diabetic (uncontrolled) children than 
controls; this reflects the important role of insulin 
therapy on both of ghrelin and glucose levels and 
the relation between them. 
As uncontrolled diabetes is characterized by 
profound insulinopenia, severe hyperglycemia, 
hyperphagia29, and if this hyperphagia does not 
keep pace with the glycosuria, loss of body fat arise 
with clinical weight loss and diminished 
subcutaneous fat stores22. 
The elevated plasma ghrelin level in poor 
glycemic controlled (uncontrolled) diabetic patients 
in our study may be due to the negative association 
between systemic ghrelin and insulin levels30, and 
the negative association between plasma ghrelin 
and both of weight and BMI in children23. 
Our results showed that there were no 
statistically significant differences regarding plasma 
ghrelin levels between good glycemic controlled 
diabetic (controlled) children and controls. These 
results are in agreement with another study21 which 
reported a significant reduction in the mean plasma 
ghrelin levels in diabetic patients after 3 months of 
insulin therapy in comparison with its higher level 
at time of diagnosis, Also this is in agreement with 
other reports found that mean plasma ghrelin levels 
decreased after insulin therapy in diabetic patients20. 
Proper insulin supplementation improves 
insulin deficiency and also improves the glycemic 
state nearly to a normal level in this group and this 
plays a great role in reduction of  the plasma ghrelin 
level21, also increased BMI in those patients may 
share in this reduction. 
Saad et al., 200231 reported that insulin could 
mediate the effect of chronic energy balance on 
plasma ghrelin. The lower insulin level as in lean 
subjects leads to increased ghrelin concentration, so 
changes in insulinemia could also underlie the 
decrease in plasma ghrelin and weight gain. 
Ashraf et al., 200721 reported that exogenous 
and endogenous insulin has been shown to have a 
negative association with ghrelin while maintaining 
euglycemia. This suggests that insulin treatment or 
an improved metabolic profile may conceivably 
play a role in reducing plasma ghrelin, thus 
mitigating the hyperphagia which often 
accompanies poorly controlled diabetes. Our results 
infer that improved glycemic control after insulin 
therapy in diabetic children plays an important role 
in pre-prandial ghrelin regulation. 
Significant negative correlations were present 
between plasma ghrelin levels and weight, weight 
on centile, BMI, and BMI on centile in all diabetic 
children. These results were in agreement with 
other studies20,21. 
Celi et al., 200530 reported a negative 
association between systemic ghrelin and insulin 
levels, this may explain the decline in plasma 
ghrelin level in children with good glycemic 
control. 
In this study a significant negative correlations 
was present between plasma ghrelin level and both 
of  fasting and 2-hours post-prandial blood glucose 
levels in all diabetic groups so the overall picture 
indicates a functional link between ghrelin, the 
insulin secretion and glucose metabolism, these 
results are in accordance with other studies20,21,32. 
However, the physiological and pathological 
importance of this link remains mostly unclear . 
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We found no significant correlations between 
plasma ghrelin concentrations and either of 
triglycerides or total cholesterol levels in all 
diabetic groups. However this contradicts with the a 
study reported that pre-prandial plasma ghrelin 
levels were negatively correlated with serum 
triglycerides and positively correlated with hyper 
density-lipoprotein (HDL) cholesterol in boys not 
in girls with no explanation33. Moreover,  other 
studies found that serum triglycerides decrease and 
HDL cholesterol increase significantly with 
increasing plasma ghrelin levels in a study 
conducted in middle-aged adults not in children34.       
Children with diabetes mellitus in all groups, 
showed no correlation between plasma ghrelin level 
and HA1c. This result was in agreement with 
Soriano-Guillen et al, 2004 and Ashraf et al, 
200720,21 who reported the same results. 
In the present study, multiple regression 
analysis of factors affecting pre-prandial plasma 
ghrelin level revealed that the most important and 
significant factors affecting ghrelin levels were 
fasting blood glucose, 2-hours post-prandial 
glucose, weight and BMI consequently supporting 
the strong relationship between ghrelin level and 
the previous parameters, while the least important 
factors were HbA1C, triglyceride and sex. It is 
possible that plasma glucose concentrations are 
stronger regulators of plasma ghrelin than HbA1c, 
which is a substitute marker of chronic glycemia in 
T1DM patients.  
In conclusion, pre-prandial  plasma ghrelin 
level increased in newly diagnosed and poorly 
controlled children with T1DM . Significant 
negative correlations between Pre-prandial  ghrelin 
level and weight , BMI , fasting and 2-hours post-
prandial levels were present. Insulin therapy and 
improvement of  blood glucose levels play an 
important role in normalizing plasma ghrelin level 
in good glycemic controlled T1DM children. No 
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